Kylonova (Xiamen) Biopharma

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
Lipoprotein(a)RNA / oligonucleotide
Atherosclerotic Cardiovascular Disease
Phase 1
APOC3RNA / oligonucleotide
Cardiovascular Disease / Dyslipidemia
Hypertriglyceridemia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.